Core Viewpoint - 盈康生命 reported a solid performance in the first half of the year, with both revenue and net profit showing growth, indicating a trend of high-quality development in the company. Financial Performance - The company achieved operating revenue of 843 million yuan, a year-on-year increase of 2.4% [1] - Net profit attributable to shareholders reached 61.83 million yuan, up 12.8% year-on-year [1] - The net profit after deducting non-recurring items was 60.59 million yuan, reflecting a 19.2% increase [1] - Gross margin improved by 0.5 percentage points, while expense ratio decreased by 2 percentage points, showcasing operational efficiency [1] Business Development - In the medical services sector, the company is advancing its tumor ecosystem evolution and differentiation strategy, with medical services revenue reaching 653 million yuan, a 2.28% increase [2] - Tumor-related revenue grew significantly by 25.14% to 215 million yuan, driven by increased patient visits and a rise in advanced tumor surgeries [2] - The company expanded its regional presence by acquiring Changsha Kexin Tumor Hospital, enhancing its capabilities in minimally invasive tumor treatments [2] AI Integration - The company has implemented a "medical + AI" strategy, leading to improved service capacity and efficiency, with a 10% year-on-year increase in per capita service volume [3] - Overall expense ratio was optimized to 15.7%, a 2 percentage point improvement [3] Medical Device Growth - The company achieved significant growth in its medical device segment, with overseas revenue increasing by 35% due to targeted strategies [4] - In the domestic market, the company’s products are undergoing high-end upgrades, with a coverage rate exceeding 40% in top-tier hospitals [4] - The company’s infusion pumps and mammography equipment have gained a market share of over 10%, ranking third in their respective categories [4] - The company has expanded its global presence by adding nine overseas distributors, enhancing its market reach across various regions [4]
盈康生命:上半年营收净利双增 医疗器械实现高增长